These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
259 related articles for article (PubMed ID: 35867811)
1. Interferon resistance of emerging SARS-CoV-2 variants. Guo K; Barrett BS; Morrison JH; Mickens KL; Vladar EK; Hasenkrug KJ; Poeschla EM; Santiago ML Proc Natl Acad Sci U S A; 2022 Aug; 119(32):e2203760119. PubMed ID: 35867811 [TBL] [Abstract][Full Text] [Related]
2. Interferon Resistance of Emerging SARS-CoV-2 Variants. Guo K; Barrett BS; Mickens KL; Vladar EK; Morrison JH; Hasenkrug KJ; Poeschla EM; Santiago ML bioRxiv; 2021 Dec; ():. PubMed ID: 33758840 [TBL] [Abstract][Full Text] [Related]
3. Cross-Neutralization of Emerging SARS-CoV-2 Variants of Concern by Antibodies Targeting Distinct Epitopes on Spike. Changrob S; Fu Y; Guthmiller JJ; Halfmann PJ; Li L; Stamper CT; Dugan HL; Accola M; Rehrauer W; Zheng NY; Huang M; Wang J; Erickson SA; Utset HA; Graves HM; Amanat F; Sather DN; Krammer F; Kawaoka Y; Wilson PC mBio; 2021 Dec; 12(6):e0297521. PubMed ID: 34781736 [TBL] [Abstract][Full Text] [Related]
4. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection. Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290 [TBL] [Abstract][Full Text] [Related]
5. Emerging mutation patterns in SARS-CoV-2 variants. Ostrov DA; Knox GW Biochem Biophys Res Commun; 2022 Jan; 586():87-92. PubMed ID: 34837837 [TBL] [Abstract][Full Text] [Related]
6. Omicron Spike confers enhanced infectivity and interferon resistance to SARS-CoV-2 in human nasal tissue. Shi G; Li T; Lai KK; Johnson RF; Yewdell JW; Compton AA Nat Commun; 2024 Jan; 15(1):889. PubMed ID: 38291024 [TBL] [Abstract][Full Text] [Related]
7. Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine. Melo-González F; Soto JA; González LA; Fernández J; Duarte LF; Schultz BM; Gálvez NMS; Pacheco GA; Ríos M; Vázquez Y; Rivera-Pérez D; Moreno-Tapia D; Iturriaga C; Vallejos OP; Berríos-Rojas RV; Hoppe-Elsholz G; Urzúa M; Bruneau N; Fasce RA; Mora J; Grifoni A; Sette A; Weiskopf D; Zeng G; Meng W; González-Aramundiz JV; González PA; Abarca K; Ramírez E; Kalergis AM; Bueno SM Front Immunol; 2021; 12():747830. PubMed ID: 34858404 [TBL] [Abstract][Full Text] [Related]
8. Immunogenicity of convalescent and vaccinated sera against clinical isolates of ancestral SARS-CoV-2, Beta, Delta, and Omicron variants. Banerjee A; Lew J; Kroeker A; Baid K; Aftanas P; Nirmalarajah K; Maguire F; Kozak R; McDonald R; Lang A; Gerdts V; Straus SE; Gilbert L; Li AX; Mozafarihashjin M; Walmsley S; Gingras AC; Wrana JL; Mazzulli T; Colwill K; McGeer AJ; Mubareka S; Falzarano D Med; 2022 Jun; 3(6):422-432.e3. PubMed ID: 35437520 [TBL] [Abstract][Full Text] [Related]
14. Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment. Chen L; Zody MC; Di Germanio C; Martinelli R; Mediavilla JR; Cunningham MH; Composto K; Chow KF; Kordalewska M; Corvelo A; Oschwald DM; Fennessey S; Zetkulic M; Dar S; Kramer Y; Mathema B; Germer S; Stone M; Simmons G; Busch MP; Maniatis T; Perlin DS; Kreiswirth BN mSphere; 2021 Aug; 6(4):e0048021. PubMed ID: 34431691 [TBL] [Abstract][Full Text] [Related]
15. Previous Infection Combined with Vaccination Produces Neutralizing Antibodies with Potency against SARS-CoV-2 Variants. Ibarrondo FJ; Hofmann C; Ali A; Ayoub P; Kohn DB; Yang OO mBio; 2021 Dec; 12(6):e0265621. PubMed ID: 34872349 [TBL] [Abstract][Full Text] [Related]
16. The Effective Inhibitory Concentration of Interferon-β Correlates with Infectivity and Replication Fitness of SARS-CoV-2 Variants. Singh J; Anantharaj A; Kumar P; Pandey R; Pandey AK; Medigeshi GR J Interferon Cytokine Res; 2024 Jul; 44(7):325-333. PubMed ID: 38557204 [TBL] [Abstract][Full Text] [Related]
17. Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines. Yang Y; Zang J; Xu S; Zhang X; Yuan S; Wang H; Lavillette D; Zhang C; Huang Z Viruses; 2021 Jul; 13(8):. PubMed ID: 34452287 [TBL] [Abstract][Full Text] [Related]
18. Haplotype distribution of SARS-CoV-2 variants in low and high vaccination rate countries during ongoing global COVID-19 pandemic in early 2021. Bui NN; Lin YT; Huang SH; Lin CW Infect Genet Evol; 2022 Jan; 97():105164. PubMed ID: 34848355 [TBL] [Abstract][Full Text] [Related]
19. In Silico Genome Analysis Reveals the Evolution and Potential Impact of SARS-CoV-2 Omicron Structural Changes on Host Immune Evasion and Antiviral Therapeutics. Chauhan D; Chakravarty N; Jeyachandran AV; Jayakarunakaran A; Sinha S; Mishra R; Arumugaswami V; Ramaiah A Viruses; 2022 Nov; 14(11):. PubMed ID: 36366559 [TBL] [Abstract][Full Text] [Related]
20. Characterization of SARS-CoV-2 Variants B.1.617.1 (Kappa), B.1.617.2 (Delta), and B.1.618 by Cell Entry and Immune Evasion. Ren W; Ju X; Gong M; Lan J; Yu Y; Long Q; Kenney DJ; O'Connell AK; Zhang Y; Zhong J; Zhong G; Douam F; Wang X; Huang A; Zhang R; Ding Q mBio; 2022 Apr; 13(2):e0009922. PubMed ID: 35266815 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]